Ensysce Biosciences, Inc.
ENSCEnsysce Biosciences is a clinical-stage biotechnology company focused on developing next-generation opioid pain relief therapies designed to prevent drug abuse and overdose.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
Ensysce Biosciences is a clinical-stage biotechnology company focused on developing next-generation opioid pain relief therapies designed to prevent drug abuse and overdose. The company utilizes two proprietary molecular delivery platforms, TAAP and MPAR, to ensure active medications are only released through specific physiological triggers in the digestive tract. Their core value proposition is providing effective pain management while mitigating the societal risks of prescription drug misuse and accidental ingestion.
Clinical-stage innovator with FDA Breakthrough Therapy designation for its overdose protection platform.
Questions, answered.
- What is Ensysce Biosciences, Inc.'s market cap?
- Ensysce Biosciences, Inc. (ENSC) has a market capitalization of $4.0M and trades on NASDAQ.
- Who are Ensysce Biosciences, Inc.'s competitors?
- Ensysce Biosciences, Inc.'s key competitors include Collegium Pharmaceutical, Inc., Vertex Pharmaceuticals, Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does Ensysce Biosciences, Inc. partner with?
- Ensysce Biosciences, Inc.'s notable partners include Quotient Sciences, National Institutes of Health, National Institute on Drug Abuse.
- Where is Ensysce Biosciences, Inc. headquartered?
- Ensysce Biosciences, Inc. is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2021.